Improvements were gradual and persisted for several years.
Few studies describe the long-term cognitive dysfunction experienced by people with anti–N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. In the current prospective, longitudinal study, investigators evaluated 40 adults with anti-NMDAR encephalitis at two consecutive visits, the first at a median of 2.3 years after symptoms onset, and the second at a median of 4.9 years after onset.
At the first visit, all patients had cognitive deficits, which were severe in 50%, moderate in 35%, and mild in 15%. The most prevalent abnormalities were executive function, working memory, and verbal memory. At the second visit, all patients showed improvement; overall, 30% had severe cognitive impairment, 35% moderate impairment, 27.5% mild, and 7.5% w…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)